Lo Sasso Bruna, Giglio Rosaria Vincenza, Vidali Matteo, Scazzone Concetta, Bivona Giulia, Gambino Caterina Maria, Ciaccio Anna Maria, Agnello Luisa, Ciaccio Marcello
Department of Biomedicine, Neurosciences and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, University of Palermo, 90127 Palermo, Italy.
Department of Laboratory Medicine, University Hospital "P. Giaccone", 90127 Palermo, Italy.
Diagnostics (Basel). 2021 Jun 22;11(7):1135. doi: 10.3390/diagnostics11071135.
(1) Background: The evaluation of anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the individual protection against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection; (2) Methods: We evaluated anti S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 2248 vaccinated subjects without previous SARS-CoV-2 infection, 91 vaccinated individuals recovered from COVID-19, and 268 individuals recovered from COVID-19 who had not been vaccinated. Among those who were healthy and vaccinated, 352 subjects performed a re-dosing after about 72 days from the first measurement. (3) Results: Anti S-RBD IgG levels were lower in subjects with previous infection than vaccinated subjects, with or without previous infection ( < 0.001). No difference was observed between vaccinated subjects, with and without previous SARS-CoV-2 infection. Overall, anti-RBD IgG levels were higher in females than males (2110 vs. 1341 BAU/mL; < 0.001) as well as in subjects with symptoms after vaccination than asymptomatic ones (2085 vs. 1332 BAU/mL; = 0.001) and lower in older than younger subjects. Finally, a significant decrease in anti-RBD IgG levels was observed within a short period from a complete two-dose cycle vaccination. (4) Conclusions: Our results show an efficacy antibody response after vaccination with age-, time- and sex-related differences.
(1) 背景：抗刺突蛋白受体结合域（S-RBD）抗体的评估是估计个体对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的保护作用的有用工具；(2) 方法：我们通过间接化学发光免疫分析法在迈瑞800（深圳新产业生物医学工程股份有限公司，加利福尼亚）上评估了2248名无SARS-CoV-2既往感染史的接种疫苗者、91名从新冠肺炎康复的接种疫苗者以及268名未接种疫苗但从新冠肺炎康复的个体的抗S-RBD IgG水平。在健康且接种疫苗的人群中，352名受试者在首次测量后约72天进行了再次给药。(3) 结果：既往感染过的受试者的抗S-RBD IgG水平低于接种疫苗的受试者，无论有无既往感染（<0.001）。在有和无SARS-CoV-2既往感染史的接种疫苗受试者之间未观察到差异。总体而言，女性的抗RBD IgG水平高于男性（2110对1341 BAU/mL；<0.001），接种疫苗后有症状的受试者高于无症状者（2085对1332 BAU/mL；=0.001），且老年受试者低于年轻受试者。最后，在完成两剂次全程接种后的短时间内观察到抗RBD IgG水平显著下降。(4) 结论：我们的结果显示接种疫苗后产生了有效的抗体反应，且存在与年龄、时间和性别相关的差异。
